You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

一圖看懂康臣藥業（1681.HK）2023年中期業績

格隆匯 08-27 17:33

近日，腎病中成藥市場領導者康臣藥業(01681.HK)公佈截至2023年中期業績，截至2023年6月30日止六個月，收入為人民幣11.2億元，同比增加約12.7%；公司權益股東應占溢利為人民幣3.48億元，同比增加約17.2%；每股基本及攤薄盈利分別約為人民幣0.4408元及人民幣0.4367元，擬宣派每股0.15港元的中期股息。下面將通過一圖帶您看懂康臣藥業(01681.HK)2022年全年業績。

康臣藥業(01681.HK)
20240618康臣藥業01681
Relevant Stocks
康臣藥業(01681.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.